Researchers have been battling to find the cure for cancer since we began to understand what cancer really was. A cure is the ultimate goal, but most medical professionals and patients would be ecstatic even hearing about new treatments. Current cancer treatments often come rife with side effects so severe that many choose to forgo them altogether. Stopping the growth of malicious cancer cells is the main goal of treatment, and removing them altogether is even better. The problem is, this kind of treatment almost always causes damage to surrounding healthy cells.
A treatment that changes cancerous cells into healthy, supportive cells sounds ideal. Transforming malignant cells into antibodies that would attack remaining cancer cells sounds too good to be true. Thanks to a groundbreaking study by scientists at The Scripps Research Institute (TSRI), this new, powerful form of cancer therapy could really be on the horizon.
An Accidental Discovery
The laboratory team was working on therapies for certain immune cell or blood factor deficiencies when they noticed some unusual effects of antibodies on marrow cells. They had been searching for antibodies that activate growth-factor receptors on immature bone marrow cells, meaning the antibodies would be able to induce these cells to mature into specific blood cell types.
After successfully identifying a number of antibodies that activated the bone marrow cell-receptors this way, the researchers noticed that some of the antibodies were having unexpected effects on the cells. Some of them were maturing into cells that were radically different from what had been expected, such as neural cells. This got the team thinking, could this method be used to convert cancerous marrow cells (leukemia cells) into non-cancerous cells?
In the new study, Richard A. Lerner, institute professor and the Lita Annenberg Hazen professor of Immunochemistry at TSRI and senior investigator, teamed up with colleagues, including first author Kyungmoo Yea, an assistant professor of cellular and molecular biology at TSRI. They decided to test 20 of the recently discovered receptor-activating antibodies on acute myeloid leukemia cells taken from human patients. One of the antibodies ended up having an incredible impact on the leukemia cells.
Most acute myeloid leukemia cells have the thrombopoietin (TPO) receptor, a receptor the winning antibody selectively and potently activated in marrow cells. When the antibody was applied to healthy marrow cells, the cells matured into blood-platelet-producing cells (megakaryocytes). When applied to the acute myeloid leukemia cells, though, the antibody caused them to mature into dendritic cells, which are key support cells in the body’s immune system.
This alone would have been a success — the researchers had effectively transformed cancerous cells into non-cancerous, helpful immune system cells. The team pushed further, though, and found that with longer exposures to the antibodies and other regulated conditions, the dendritic cells matured even more. The final product was a group of cells that very closely resembled natural killer (NK) cells. One of the body’s rapid immune defenses, NK cells are capable of rapidly attacking potentially dangerous pathogens and tumors even if they don’t contain the biomarkers normally identified by other immune cells.
“That antibody could have turned those acute myeloid leukemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,” Lerner said in a press release.
These induced NK cells possessed a few unique characteristics, observed by the team through electron microscopy. The cells possessed extending tendrils that had made their way through the outer membranes of closeby leukemia cells — the kind of cells they would still be, had they not been exposed to the antibody. In lab tests, the NK cells betrayed their former brethren at an impressive pace: a “modest” number of NK cells took out about 15 percent of the surrounding leukemic cell population in only 24 hours.
An interesting detail noted by the researchers is the purely fratricidal nature of the NK cells. They attacked only related leukemia cells, while unrelated breast cancer cells did not die off in large numbers when put into contact with the NK cells. The team is still unclear on why exactly the NK cells behave this way, but hypothesize that other, yet-to-be-discovered antibodies could be the key to turning other cancerous cell types into NK cells.
Lerner has named this type of therapy “fratricidins,” and pointed out that they would have several advantages. The antibodies would be clinically useful with little to no modification, and the high specificity of the NK cells would reduce the likelihood of damage to surrounding healthy cells. This would make fratricidins a possible treatment with much more tolerable effects than traditional treatments like chemotherapy.
On top of that, every cancer cell in a population is potentially convertible, so in a successful therapy the cancer-cell population might not just be reduced, but eliminated entirely.
The Latest on: Cancer Treatment Breakthrough
via Google News
The Latest on: Cancer Treatment Breakthrough
- American Cancer Society's Newly Formed Philanthropic Impact Fund Makes First Investment on April 18, 2019 at 4:00 am
From breakthrough research, to free lodging near treatment, a 24/7/365 live helpline, free rides to treatment, and convening powerful activists to create awareness and impact, the Society is the only ... […]
- Scientists “Cure” Patients With “Bubble Boy” Disease In Breakthrough Treatment on April 18, 2019 at 3:40 am
He died at the age of 12 from a form of cancer called lymphoma, introduced to his delicate immune system by the Epstein-Barr virus. This, it should be noted, is not the standard course of treatment ... […]
- Genfit: GENFIT Announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC on April 17, 2019 at 10:00 pm
today announced that its lead product candidate elafibranor was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Primary Biliary Cholangitis ... […]
- Stem Cell Procedure Offering Hope Of Breakthrough Cure For Crohn’s Disease on April 17, 2019 at 5:36 pm
NEW YORK (CBSNewYork) – Doctors may now have a possible breakthrough in the treatment of the most serious ... “In some patients with both cancer and Crohn’s got a transplant,” said Dr ... […]
- Bowel cancer breakthrough could see new treatments in the pipeline on April 17, 2019 at 6:00 am
How old you are has a direct link to what type of bowel cancer you are most at risk of getting, and the treatment needed to fight it, new research from QIMR Berghofer Medical Research Institute has ... […]
- Computational researchers and oncologists develop protein cancer atlas to accelerate personalized medicine for leukemia patients on April 17, 2019 at 1:08 am
The new protein classifications will help researchers and clinicians recommend better treatment and personalized medicine for patients suffering from this aggressive cancer, which occurs in the blood ... […]
- Pasadena Startup, USC Researchers Announce Breakthrough Medical Technique to Prevent Jaw Damage from Cancer Drugs on April 15, 2019 at 5:45 am
Researchers from the University of Southern California after collaborating with a Pasadena company have reported a breakthrough technique that could prevent damage to the jaw as a side effect suffered ... […]
- Breakthrough at St. Jude Children’s Research could help in ALS treatment on April 12, 2019 at 5:19 pm
Dr. Kundu credits St. Jude’s donors and the fundraising team at ALSAC for making the breakthrough possible. “And it’s important to remember that people at St. Jude study not just cancer but other ... ... […]
- Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices on April 11, 2019 at 8:56 am
TEL AVIV, Israel, April 11, 2019 /PRNewswire/ -- Alpha Tau Medical, developer of the breakthrough alpha ... of the first alpha-radiation based cancer treatment for solid tumors, Alpha DaRT. […]
- New Cancer Treatment Shows Success, 'Vaccine' Patients In Full Remission on April 9, 2019 at 3:32 am
The treatment was referred to as an “in situ vaccine ... Still, the findings are a breakthrough in efforts to find a cure for cancer, especially after so many trials in the past have failed. […]
via Bing News